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In the PORTEC-2 trial, 427
patients with stage I
higheintermediate-risk
endometrial cancer were
randomized to external beam
radiation therapy (EBRT) or
vaginal brachytherapy. In
this 7- and 10-year health-
related quality of life anal-
ysis, patients treated with
EBRT reported a persisting
higher rate of bowel symp-
toms with impact on daily
activities, and a trend for
more urinary symptoms,
without impact on overall
quality of life or differences
in cancer survivorship issues.Purpose: To evaluate the long-term health-related quality of life (HRQL) after
external beam radiation therapy (EBRT) or vaginal brachytherapy (VBT) among
PORTEC-2 trial patients, evaluate long-term bowel and bladder symptoms, and assess
the impact of cancer on these endometrial cancer (EC) survivors.
Patients and Methods: In the PORTEC-2 trial, 427 patients with stage I higheinter-
mediate-risk EC were randomly allocated to EBRT or VBT. The 7- and 10-year HRQL
questionnaires consisted of EORTC QLQ-C30; subscales for bowel and bladder symp-
toms; the Impact of Cancer Questionnaire; and 14 questions on comorbidities, walking
aids, and incontinence pads. Analysis was done using linear mixed models for sub-
scales and (ordinal) logistic regression with random effects for single items. A two-
sided P value <.01 was considered statistically significant.
Results: Longitudinal HRQL analysis showed persisting higher rates of bowel symp-
toms with EBRT, without significant differences in global health or any of the func-
tioning scales. At 7 years, clinically relevant fecal leakage was reported by 10.6%
in the EBRT group, versus 1.8% for VBT (PZ.03), diarrhea by 8.4% versus 0.9%
(PZ.04), limitations due to bowel symptoms by 10.5% versus 1.8% (PZ.001), and
bowel urgency by 23.3% versus 6.6% (P<.001). Urinary urgency was reported by
39.3% of EBRT patients, 25.5% for VBT, PZ.05. No difference in sexual activity
was seen between treatment arms. Long-term impact of cancer scores was higher
among the patients who had an EC recurrence or second cancer.
Conclusions: More than 7 years after treatment, EBRT patients reported more bowel
symptoms with impact on daily activities, and a trend for more urinary symptoms,
without impact on overall quality of life or difference in cancer survivorship issues.
 2015 Elsevier Inc. All rights reserved.Introduction
Randomized trials have shown that pelvic external beam
radiation therapy (EBRT) significantly reduced locore-
gional relapse compared with observation after surgery, but
without survival benefit, and at the cost of mainly gastro-
intestinal adverse events (1-5). The Post Operative Radia-
tion Therapy in Endometrial Carcinoma (PORTEC)-2 trial
showed that vaginal brachytherapy (VBT) was highly
effective as compared with EBRT, with 2% vaginal recur-
rence at 5 years in both arms, and similar rates of locore-
gional relapse and overall survival (6). Health-related
quality of life (HRQL) analysis among PORTEC-2 trial
patients at 5 years showed that women treated with VBT
reported significantly fewer bowel symptoms, without
limitations in daily activities, and higher social functioning
scores than those who underwent EBRT. Symptom ratings
of VBT patients remained similar to that of an age-matched
normal population. Sexual functioning scores were lower in
both groups compared with the age-matched population (7).
On the basis of these results VBT became the standard
adjuvant treatment for patients with higheintermediate-risk
endometrial cancer (EC).
Analysis of long-term HRQL in the previous PORTEC-
1 trial, in which patients were randomized to EBRT or
observation after surgery, showed that even after 10 to
15 years, bowel symptoms were still more frequent among
patients who underwent EBRT. Urinary symptoms had
become more frequent over time in both groups, but moreclearly so among EBRT patients, with a significantly
increased use of incontinence pads (“day and night usage”
42.9% vs 15.2% and “never use” 39% vs 60% for EBRT vs
VBT, P<.001) (4, 8). For radiation therapyerelated
toxicity it is known that the bladder is a late-responding
organ (9, 10).
Little is known about the long-term impact of diagnosis
and treatment on survivors of EC. The Impact Of Cancer
(IOC) scale is a questionnaire measuring the positive and
negative impact of cancer experience among long-term
survivors (11). Translation and validation of the IOC for
use in The Netherlands have been reported (12). The IOC
version 2 (IOCv2) had similar impact domains in the Dutch
sample, providing evidence that IOCv2 measured common
and important survivor concerns across two different
Western nations.
The present analysis was done to evaluate long-term
HRQL after EBRT or VBT among PORTEC-2 trial pa-
tients, evaluate long-term bowel and bladder symptoms,
and assess the impact of cancer on these EC survivors.Patients and Methods
Patient selection and study design of the PORTEC-2
trial
Between 2002 and 2006, 427 patients with stage I highe
intermediate-risk EC who participated in the PORTEC-2
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selection, treatment, and HRQL have been described in
previous publications (6, 13). Baseline questionnaires and
at least 1 follow-up questionnaire were received from 348
of 427 patients (81% of responders). Almost all patients
had multiple follow-up questionnaires (7). For the present
analysis, patients were considered eligible if they were
previous responders and were alive and disease-free ac-
cording to the trial database.
HRQL assessment
Cancer-specific general HRQL was measured with the
EORTC (European Organization for Research and
Treatment of Cancer) Core questionnaire (QLQ-C30 v3.0)
(14). Because the EC-specific EN24 module (14) was not
yet available, subscales from EORTC modules were
combined into a bowel, bladder, and sexual symptom
module (15, 16). Likert-type response scales were used
with a 4-point response scale, except for items 29 and 30
of the EORTC QLQ-C30 (7-point scale). All subscales
and item responses were converted to 0 to 100 scales.PORTEC-2
N = 427
Missing at baseline N=79
348 (81%) responders for HRQL analysi
EBRT:  N=214
207 received EBRT
5 VBT (patient refusal)
1 (ineligible: low risk) no RT 
1 (ineligible: high risk) EBRT + VBT
VBT:  N=2
210 receiv
2 (ineligib
1 EBRT (VB
7 years, follow-up
Death / Recurrent disease / withdrawn due to
other reasons N = 82 
Current address unknown N = 1
7 -year PORTEC-2 QoL questionnaire se
N = 265
10-year QoL questionnaire sent 
(ongoing follow-up – subset reached this time
point): N = 119
Fig. 1. CONSOHigher scores for functioning items and global quality of
life scale represent a better level of functioning. For the
symptom items, a higher score reflects a higher level of
symptoms.
The HRQL questionnaire had been sent to the trial pa-
tients at 6-months intervals in the first 2 years and annually
until 5 years. The 7- and 10-year questionnaires were
supplemented with the IOCv2 and 14 extra questions on
general health, comorbidities, and use of (walking) aids and
incontinence pads.
The most recent scaling of the IOC questionnaire yiel-
ded the 37-item IOCv2, divided into 4 positive subscales
and 4 negative subscales (17). Respondents indicated their
level of agreement from 1 (strongly disagree) to 5 (strongly
agree). The PORTEC-1 trial patients had completed the
IOCv1, which has 7 items less than IOCv2. An algorithm
by Crespi et al (18) was used to impute these missing
IOCv2 items for the PORTEC-1 patients for comparison. In
view of overlapping questions, the IOCv1 question
“ongoing cancer-related or treatment-related symptoms
interfere with my life” was not asked. Therefore, the sub-
scale “life interferences” was not computed. As as  
13
ed VBT
le: low risk) no RT
T not feasible)
  
nt  Responders: 205 (77%)
Non-responder N = 60
Not evaluable N = 3 
 
Responders: 80 (67%) 
Non-responder N = 39 
Not evaluable N = 0
EBRT
7-year QoL n = 89
VBT
7-year QoL n = 113
EBRT VBT
10-year QoL n = 44 10-year QoL n = 36   
RT diagram.
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consisted of 3 instead of 4 subscales.Statistical methods
All statistical analyses were performed with SPSS version
20.0. The c2 test or Fisher exact test for categorical vari-
ables and t test for continuous variables were used to
compare patient and tumor characteristics and to compare
mean scores of symptoms at single time points (P<.05
considered significant). Because of ongoing follow up, the
10-year results were only used for longitudinal analysis.
Analysis of HRQL was done according to EORTC
Quality of Life Group guidelines. Baseline scores were
compared with a t test, or Armitage trend test for single
items. To obtain estimates of the EORTC QLQ-C30 and
subscales at each of the fixed time points, a linear mixed
model was used with patient as random effect and time
(categorical), random assignment, and their interaction as
fixed effects. Single items were analyzed using (ordinal)
logistic regression with random effects. Differences in
HRQL between the two treatment groups were tested by the
Wald test in the linear or ordinal logistic mixed model (P
random assignment), which excluded the baseline value.Table 1 Patient characteristics of patients at 7 years compared with
Characteristic
Responders and evaluable at 7 years (nZ
EBRT (nZ89) VBT (nZ113)
n % n %
Age at randomization (y)
Mean 67.1 68.1
Range 51-84 46-85
<60 6 6.7 4 3.5
60 83 93.3 109 96.5
FIGO stage (1988)z
IB 5 5.6 6 5.3
IC 77 86.5 98 86.7
IIA 7 7.9 9 8.0
Histologic grade
1 39 43.8 56 49.6
2 45 50.6 50 44.2
3 5 5.6 7 6.2
WHO performance
0 64 71.9 87 77.0
1 25 28.1 22 19.5
>2 0 0.0 4 3.5
Comorbidity
IBS 1 1.1 0 0.0
Diabetes 6 6.7 16 14.2
Hypertension 32 36.0 40 35.4
Cardiovascular 16 18.2 20 17.7
Other 10 11.2 9 8.0
Abbreviations: EBRT Z external beam radiation therapy; IBS Z irritabl
Endometrial Carcinoma; VBT Z vaginal brachytherapy; WHO Z World Hea
* P value for comparison EBRT versus VBT of responders and evaluable a
y P value for comparison responders and evaluable at 7 years (present anal
z International Federation of Gynecology and Obstetrics 1988 staging criterThe same test was applied to analyze significant changes of
QOL scores over time (P-time), and score changes over
time were compared between treatment groups (P-time by
random assignment), which included the baseline value. To
guard against false-positive results because of multiple
testing, a 2-sided P value .01 was considered statistically
significant.
Guidelines on the interpretation of clinically relevant
changes of EORTC QLQ-C30 scores were applied (19, 20).
Scales not included in the guideline were evaluated ac-
cording to Osoba et al (21), who reported that patients
valued a change of 5 to 10 as “little,” 10-20 as “moderate,”
and more than 20 as “very much” difference.
The IOC scores were compared with a t test. Analysis of
covariance was done to evaluate whether patient-related
factors influenced scores between PORTEC-1 and
PORTEC-2 patients.
Results
HRQL population and compliance
Questionnaires were sent to 265 eligible patients with
correct current address at the time points 7 years andall PORTEC-2 patients
202) All patients PORTEC-2 (nZ427)
P*
EBRT (nZ214) VBT (nZ213)
Pyn % n %
.28 69.3 69.8 .001
51-89 46-85
8 3.7 8 3.8
206 96.3 205 96.2
.94 .81
19 8.9 16 7.5
172 80.4 171 80.3
23 10.7 26 12.2
.55 .74
99 46.3 103 48.4
97 44.1 94 44.1
18 8.4 16 7.5
.83 .32
157 73.4 141 66.5
56 26.2 66 31.1
1 0.5 5 2.4
.32 4 1.9 2 0.9 .23
.08 28 13.1 34 16.0 .19
.94 75 35.2 75 35.5 .95
.93 47 22.2 51 24.1 .13
.43 33 15.4 33 15.6 .02
e bowel syndrome; PORTEC Z Post Operative Radiation Therapy in
lth Organization performance score.
t 7 years.
ysis) versus the initial PORTEC-2 cohort.
ia.
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7 years was 205 of 265 (77%). Three patients only
answered the comment page and were therefore not
evaluable. One hundred nineteen patients had reached the
10-year time point, of whom 80 (67%) returned the
questionnaire (Fig. 1).
Of the 282 evaluable questionnaires (202 7-year and 80
10-year questionnaires), 76.2% had completed all items of
the QLQ-C30, with rates of completion for the bladder and
bowel items of 90.8% and 93.97%, respectively, and 69.8%
for sexuality items. Among the responders who indicated to
be sexually active (nZ45), 86.7% had completed the sexual
symptom subscale.
In the “remarks” section, 7 patients (2 EBRT, 5 VBT, of
whom 1 only at 10 years) noted having been diagnosed
with a second cancer in the pelvic region or an EC recur-
rence. Because this was not yet known in the trial database,
this information was verified and proved correct in all
cases. A second cancer outside the pelvic region was re-
ported by another 5 patients. To avoid analysis of symp-
toms that could have been caused by a second cancer or
recurrence, patients with an EC recurrence or a second
cancer in the pelvic region were excluded for longitudinal
and symptom analysis. The patients with an EC recurrenceA B
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General functioning
Table 1 shows the patient characteristics, both of the current
participants and for the complete PORTEC-2 trial popula-
tion. Responders at 7 years were slightly younger and had
fewer comorbidities compared with the whole PORTEC-2
cohort; no other significant differences were found.
Scores on the QLQ-C30 functioning and global health
scales did not significantly differ between the 2 treatment
groups (Fig. 2, Table 2). Although the overall longitudinal
analysis found higher social functioning scores in the VBT
group (PZ.04), these higher scores were observed in the
first 2 years after treatment, and similar thereafter.
Sexual activity was reported by only 19.4% of the pa-
tients, sexual interest by 28.1%. No difference in sexual
interest and sexual activity was seen between treatment
arms. Among patients who were sexually active, 87%
(nZ20) of EBRT patients reported sex to be enjoyable,
compared with 50% (nZ15) of VBT patients (PZ.001).
Symptoms ratings of vaginal dryness, shortening, or pain
were not significantly different between the treatment arms.Ba
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a higher level of functioning or activity. For (C) (Diarrhea)
vel of symptoms. Abbreviations: EBRT Z external beam
chytherapy.
Table 2 Mean scores of QLQ-C30 functioning scales and symptom ratings by treatment arm
Parameter Baseline
Questionnaire
time points P
84 mo 120 mo Time Randomization Time  randomization
EORTC QLQ-C30
Global health <.001 .58 .96
EBRT 69.3 76.9 76.7
VBT 70.4 76.2 77.3
Functioning scales
Social functioning <.001 .04 .04
EBRT 77.6 91.8 92.0
VBT 78.1 89.8 92.0
Cognitive functioning .35 .30 .60
EBRT 84.3 86.5 84.7
VBT 86.7 85.5 86.7
Emotional functioning <.001 .33 .71
EBRT 75.6 82.9 83.7
VBT 76.3 84.7 87.5
Physical functioning <.001 .34 .75
EBRT 72.0 74.9 68.4
VBT 73.7 73.3 69.2
Role functioning <.001 .34 .15
EBRT 61.0 80.3 71.2
VBT 59.1 76.9 77.5
QLQ-C30 symptom scoring
Fatigue <.001 .14 .37
EBRT 34.8 25.6 25.0
VBT 34.1 26.2 25.6
Nausea and vomiting <.001 .04 .34
EBRT 4.6 2.8 3.9
VBT 5.0 2.4 3.7
Pain <.001 .33 .46
EBRT 18.5 14.2 22.1
VBT 19.4 17.0 15.1
Dyspnea <.001 .53 .05
EBRT 13.0 18.6 21.8
VBT 11.6 14.6 19.6
Insomnia .003 .17 .58
EBRT 27.4 20.2 29.6
VBT 25.9 23.3 21.5
Appetite loss <.001 .03 .02
EBRT 13.7 8.6 8.8
VBT 10.6 8.2 4.3
Constipation <.001 .56 .79
EBRT 13.4 8.3 5.7
VBT 12.9 7.4 9.1
Diarrhea <.001 <.001 <.001
EBRT 7.9 10.3 14.7
VBT 4.9 4.2 3.5
Financial difficulties .003 .85 .26
EBRT 2.0 2.3 2.0
VBT 5.5 2.3 3.1
Bowel symptoms (BS)
Limitation of daily activities due to BS <.001 <.001 .001
EBRT 9.0 12.7 14.1
VBT 5.0 4.9 6.2
Fecal leakage <.001 <.001 .06
EBRT 4.0 12.1 13.4
VBT 1.5 5.6 3.0
(continued on next page)
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Table 2 (continued )
Parameter Baseline
Questionnaire
time points P
84 mo 120 mo Time Randomization Time  randomization
Rectal blood loss .08 .06 .51
EBRT 0.4 1.2 1.0
VBT 0.2 1.1 0.1
Bloated feeling <.001 .16 .78
EBRT 15.8 16.0 11.2
VBT 15.5 10.9 8.0
Urinary symptoms (US)
Frequency daytime <.001 .16 .09
EBRT 33.2 35.0 43.4
VBT 36.5 32.0 33.1
Frequency at night <.001 .21 .05
EBRT 31.5 36.3 46.4
VBT 34.3 35.3 37.2
Urinary urgency <.001 .20 .05
EBRT 23.4 40.5 46.2
VBT 23.9 32.7 42.3
Sleep deprivation due to urinary frequency .001 .10 .18
EBRT 15.3 18.9 25.8
VBT 16.2 14.0 17.4
Need to remain close to the toilet <.001 .001 .004
EBRT 7.8 16.2 23.4
VBT 7.0 10.2 12.8
Incontinence for urine <.001 .19 .24
EBRT 11.5 20.4 29.8
VBT 10.6 20.8 25.5
Dysuria <.001 .91 .87
EBRT 5.3 3.9 2.2
VBT 7.9 3.2 2.0
Limitation daily activities due to US <.001 .03 .25
EBRT 3.6 12.4 14.2
VBT 3.0 7.3 7.3
Sexual functioning and symptoms
Sexual interest <.001 .24 .26
EBRT 7.7 13.8 8.1
VBT 4.9 8.1 2.2
Sexual activity <.001 .34 .82
EBRT 5.3 7.3 5.3
VBT 2.8 6.4 0.0
To what extent was sex enjoyable .004 .30 <.001
EBRT 45.7 46.1 19.7
VBT 20.0 25.1 43.5
Vaginal dryness .83 .66 .07
EBRT 30.9 29.6 25.3
VBT 36.4 28.9 51.9
Abbreviations as in Table 1.
P time: changes of quality-of-life scores over time. P randomization: difference in health-related quality of life between the 2 treatment groups. P
time  randomization: quality-of-life score changes over time between the 2 treatment groups.
Mean scores of earlier time points have previously been reported by Nout et al (7).
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Longitudinal analysis throughout the 10-year HRQL
follow-up period showed higher rates of diarrhea, fecal
leakage, and limitations in daily activities due to bowelsymptoms in the EBRT group as compared with VBT (all
P<.001; Table 2), similar to previous analyses (8). At
7 years, significant and clinically relevant differences
between EBRT and VBT patients were found for all bowel
symptoms except for rectal blood loss, flatulence, and
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Fig. 3. Patient symptom scores at 7 years for (A) diarrhea, (B) bowel urgency, (C) fecal leakage, (D) limitation of daily
activities due to bowel symptoms, (E) urinary urgency, (F) sleep deprivation due to urinary frequency, (G) need to remain
close to the toilet, and (H) limitation of daily activities due to urinary symptoms.
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Table 3 Single-item scores bowel, bladder, and sexual symptoms at 7 years (nZ196)*
Treatment
No.
missing
No. of patients
without
symptoms
% of
patients
No. of patients
with mild
symptoms*
% of
patients
No. of
patients with
moderate/severe
symptoms*
% of
patients
t test
mean
scores
Bowel symptoms (BS)
Diarrhea .037
EBRT 5 65 78.3 11 13.3 7 8.4
VBT 2 93 87.7 12 11.3 1 0.9
Limitation of daily activities due to BS .001
EBRT 2 58 67.4 19 22.1 9 10.5
VBT 2 93 87.7 11 10.4 2 1.8
Fecal leakage .03
EBRT 3 64 75.3 12 14.1 9 10.6
VBT 1 91 85 14 13.1 2 1.8
Rectal blood loss .83
EBRT 2 84 97.7 1 1.2 1 1.2
VBT 2 103 97.2 3 2.8 0 0.0
Bloated feeling .04
EBRT 2 56 65.1 21 24.4 9 10.5
VBT 2 81 76.4 21 19.8 4 3.8
Bowel urgency <.001
EBRT 2 38 44.2 28 32.6 20 23.3
VBT 2 71 67 28 26.4 7 6.6
Flatulence .76
EBRT 3 36 42.4 31 36.5 18 21.2
VBT 2 54 50.9 40 37.7 12 11.3
Stomach/bowel cramps .12
EBRT 2 63 73.3 18 20.9 5 5.9
VBT 2 88 83.0 14 13.2 4 3.8
Urinary symptoms (US)
Frequency daytime .58
EBRT 5 29 34.9 31 37.3 23 27.7
VBT 2 40 37.7 41 38.7 25 23.6
Frequency at night .56
EBRT 3 20 23.5 40 47.1 25 29.4
VBT 2 35 33.0 42 39.6 29 27.4
Urinary urgency .05
EBRT 4 27 32.1 24 28.6 33 39.3
VBT 2 41 38.7 38 35.8 27 25.5
Sleep deprivation due to urinary frequency .06
EBRT 4 50 59.5 23 27.4 11 13.1
VBT 3 77 73.3 21 20.0 7 6.7
Need to remain close to the toilet .07
EBRT 4 54 64.3 23 27.4 7 8.4
VBT 4 82 78.8 16 15.4 6 5.7
Incontinence for urine .89
EBRT 4 48 57.1 26 31.0 10 11.9
VBT 4 57 54.8 38 36.5 9 8.7
Dysuria .35
EBRT 4 76 90.5 5 6.0 3 3.6
VBT 6 96 94.1 4 3.9 2 2.0
Limitation of daily activities due to US .11
EBRT 1 63 72.4 20 23.0 4 4.6
VBT 1 90 84.1 13 12.1 4 3.7
Difficulties emptying of the bladder .19
EBRT 4 66 78.6 13 15.5 5 6.0
VBT 4 89 85.6 12 11.5 3 2.9
Sexual symptomsy
(continued on next page)
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Table 3 (continued )
Treatment
No.
missing
No. of patients
without
symptoms
% of
patients
No. of patients
with mild
symptoms*
% of
patients
No. of
patients with
moderate/severe
symptoms*
% of
patients
t test
mean
scores
To what extent was sex enjoyable .001
EBRT 65 3 13.0 8 34.8 12 52.2
VBT 78 15 50.0 9 30.0 6 20.0
Vaginal dryness .763
EBRT 67 11 52.4 3 14.3 7 33.4
VBT 78 18 60.0 4 13.3 8 26.7
Short or narrow vagina .190
EBRT 66 13 59.1 8 36.4 1 4.5
VBT 79 16 55.2 7 24.1 6 20.6
Pain during intercourse .122
EBRT 66 17 77.3 4 18.2 1 4.5
VBT 81 17 63.0 6 22.2 4 14.8
Abbreviations as in Table 1. BS Z bowel symptoms; US Z urinary symptoms.
At 7 years there were 202 responders; 6 patients were excluded owing to endometrial cancer recurrence or second cancer in the pelvic region.
* Mild symptoms: response “a little”; moderate/severe symptoms: response “quite a bit” or “very much.”
y Responses to these questions were only expected if the respondent indicated to be sexually active.
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symptoms of fecal leakage were reported by 10.6% versus
1.8% of EBRT versus VBT patients (PZ.03), and mod-
erate or severe diarrhea by 8.4% versus 0.9% (PZ.037).
Limitations in daily activities due to bowel symptoms
were reported by 10.5% versus 1.8% (PZ.001) and bowel
urgency by 23.3% versus 6.6% (P<.001).
No differences were found in use of incontinence pads
for fecal soiling (10.6% vs 8.1% for EBRT vs VBT). Fifty
percent of patients who reported limitations in daily func-
tioning due to bowel symptoms or fecal leakage used in-
continence pads.
Longitudinal analysis of 10-year HRQL follow-up for
urinary symptoms showed increasing rates of urinary ur-
gency and nocturnal frequency over time in both groups,
but more so among EBRT patients (PZ.05). Patients
treated with EBRT reported higher rates of remaining close
to the toilet because of urinary symptoms (PZ.001;
Table 2). Over time, increasing rates of urinary urgency
were found, and at 7 years significantly more EBRT pa-
tients reported urinary urgency, a difference that was not
seen in the 5-year HRQL analysis. Moderate or severe
symptoms of urinary urgency were reported by 39.3%
versus 25.5% (EBRT vs VBT, PZ.05). Rates of sleep
disturbance due to urinary frequency (13.1% vs 6.7%,
PZ.06) and the need to remain close to the toilet (8.4% vs
5.7%, PZ.07) were slightly but nonsignificantly higher
among EBRT patients (Fig. 3, Table 3).
Overall, 50% of patients reported use of incontinence
pads, without differences between the groups (50.6% vs
50.9%). Use of incontinence pads was reported by 85.2%
of patients with urinary incontinence and 87.2% of those
with limitations in daily activities due to urinary
symptoms.IOC scores
All scales for the IOC questionnaire could be computed
for 176 of 190 patients (92.6%). No differences in any of
the subscales were seen between the 2 PORTEC-2
treatment arms. Comparison of PORTEC-2 IOC
scores with PORTEC-1 scores showed that PORTEC-1
patients tended to have higher scores on every subscale
and overall scales (Fig. 4 and Table E1 [available online
at www.redjournal.org]). Analysis of covariance
(adjusted for the presence of bone problems, having a
partner, and age) showed that PORTEC-1 patients scored
higher on the positive impact domain (3.03 vs 2.82,
PZ.002).
Differences in IOC scores were found between the 51
patients who had reported to have been diagnosed and
treated for EC recurrence or second cancer (PORTEC-1
nZ39, PORTEC-2 nZ12), compared with the combined
general PORTEC-1 and -2 patients. These patients had
significantly higher scores on all IOC subscales, except for
meaning of cancer (Fig. 4).
Discussion
This long-term analysis of HRQL in the PORTEC-2 trial
shows that EBRT may have a long-lasting, clinically rele-
vant, mostly bowel symptomerelated negative impact on
HRQL, with moderate or severe limitation of daily activ-
ities reported by 10% of the patients. Patients treated with
EBRT reported significantly more diarrhea, fecal leakage,
urgency, and limitations in daily activities due to bowel
symptoms compared with VBT. At 7 years, for the first
time significantly more urinary urgency was reported by
patients treated with EBRT.
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Fig. 4. Impact of cancer scores at 7 years of (A) patients treated in the Post Operative Radiation Therapy in Endometrial
Carcinoma (PORTEC)-1 versus PORTEC-2 trial; and (B) patients in PORTEC-1 and PORTEC-2 with recurrence or a second
cancer versus patients without recurrence or second cancer.
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reported gastrointestinal and bladder symptoms after pelvic
EBRT in a randomized trial, with the strengths of exclusion
of biases due to the randomized comparison and the com-
plete follow-up. Our results are consistent with the rates of
gastrointestinal and bladder toxicity found in other studies
(22-24). Although the differences in mean scores were
small, 10% of patients reported to have moderate or severe
limitations of daily activities, and this is clinically relevant
(19, 20).These patient-reported outcomes provide a complete
picture of survivorship issues after treatment of EC,
because agreement between patient- and physician-based
scoring of toxicities is low, with significant underreporting
of lower-grade toxicities that do impact daily life (25).
Similar to the long-term quality-of-life analysis of the
PORTEC-1 trial, we found that urinary symptoms with use
of incontinence pads was not reported until more than
5 years after treatment, showing the combined effects of
aging and EBRTon the bladder and pelvic floor. It is known
de Boer et al. International Journal of Radiation Oncology  Biology  Physics808from previous studies that the bladder is a late-responding
organ (8-10) and that pelvic floor dysfunction gradually
develops over time.
General functioning and global health did not signifi-
cantly differ between EBRT and VBT patients, suggesting
that diagnosis and treatment of EC have a transient impact
on patient functioning and that many patients adjust their
lives to bothersome but manageable symptoms.
Sexual activity and interest were reported by only 19.3%
and 28.1% of the patients at 7 years, without differences
between EBRT and VBT. Patients treated with EBRT more
often (87% vs 51%) reported sex to be enjoyable, whereas
there were no differences in symptoms such as vaginal
dryness or pain. The low activity rates together with the low
completion rate of the sexual functioning questions are a
limitation to these findings.
The challenge is to develop preventive and intervention
measures that might reduce or prevent such long-lasting
symptoms caused by EBRT. Andreyev et al (26) reported
clinical improvement in bowel function with a structured,
algorithm-driven approach. Pelvic floor muscle training
programs for gynecologic cancer survivors with pelvic floor
dysfunction showed improved results compared with no
intervention (27, 28). It remains to be seen whether in-
struction on simple pelvic floor exercises for all patients
will reduce symptoms and dysfunction over time.
Another possible limitation to this analysis is the
inherent selection of responders at long-term analysis,
because participants had to be alive and disease-free.
Previous analyses had shown no differences in patient or
tumor characteristics between responders and non-
responders (7). The patients in the present analysis were
slightly younger and had fewer comorbidities. With a
mean age of the PORTEC-2 patients of 69 years, the older
patients with more comorbidities were at higher risk to die
of intercurrent disease compared with the younger pa-
tients. Another explanation could be that the older patients
were not able to respond owing to other reasons, such as
vision problems or cognitive disorders. With the high
response rate of 77% at 7 years, however, these results are
generally applicable.
No differences in IOC scores were seen between patients
in the PORTEC-2 treatment arms. Comparison of
PORTEC-1 and PORTEC-2 patients showed higher scores
on positive impact scales among PORTEC-1 patients.
Younger patients and those with a partner had higher scores
on the positive impact domain scales, whereas patients with
bone or joint problems scored higher on the negative
impact scales. Oerlemans et al (12) reported in a study
among non-Hodgkin lymphoma survivors fewer positive
and more negative impacts of cancer in Dutch survivors
compared with American non-Hodgkin lymphoma survi-
vors. They suggested that IOC scores might be more
dependent on cultural background than type of cancer. Age,
length of follow-up, female gender, education level, rela-
tionship, and employment were factors of influence (12). In
Table E1 (available online at www.redjournal.org) anoverview of the IOC scores from these 4 different study
groups is shown.
The higher IOC scores among patients who had been
diagnosed with EC recurrence or second cancer reflect their
having to cope with the stresses and anxieties of having had
cancer for the second time, and additional symptoms of
renewed treatment.
In conclusion, this study shows the long-lasting, clini-
cally relevant, mostly bowel symptomerelated negative
impact of EBRT on HRQL of a significant minority of the
patients, although not significantly influencing general
health and overall quality of life. External beam radiation
therapy should be used only when the benefit outweighs the
risks of toxicity. These results provide important informa-
tion to be used for patient counseling and shared decision
making regarding costs and benefits of adjuvant treatment.
Future studies should be aimed at methods to prevent or
improve these symptoms. The reduction of such long-term
symptoms might be achieved by using new radiation
techniques. First studies of intensity modulated radiation
therapy have shown lower rates of both acute and late
symptoms (29-31). Preventive measures for pelvic floor
function should be investigated.References
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